Navigation Links
Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
Date:4/3/2011

a composite of death, myocardial infarction (MI), urgent target vessel revascularization (TVR) or recurrent ischemia at 30 days.  

Previously presented data from RADAR (AHA, November 2010) confirmed that pegnivacogin dosed at 1mg/kg reproducibly resulted in near complete inhibition of FIXa in an ACS population.  The latest RADAR results showed that ACUITY major bleeding following immediate sheath removal exhibited a dose response with bleeding rates decreasing with increasing levels of reversal.  Rates of bleeding were lower in the 75% and 100% reversal arms than heparin.  In addition, the incidence of ischemic events was lower in REG1 treated patients compared with those treated with heparin.  

Adverse events (AEs) other than bleeding and ischemic events were rare and evenly distributed among the arms of the study.  Three patients, clustered late in the trial and in Europe, had allergic-like reactions shortly after receiving pegnivacogin.  Characterization of these reactions is ongoing.  

"We are thrilled by the results of RADAR and the groundbreaking advance in anticoagulant therapy that they foretell.  It is now clear that control matters.  REG1 uniquely has shown the promise of simultaneously reducing ischemia and bleeding in comparison to heparin," said Dr. David J. Mazzo, President and CEO of Regado Biosciences, Inc.  He added, "The results of the RADAR trial solidly support Phase 3 development of REG1 in the broader ACS population.  Regado plans to move forward in this indication as well as in a parallel indication of open heart surgery."  

"The Phase 2b RADAR results suggest that high intensity FIXa inhibition with active control may ultimately represent a potential treatment option for addressing both ischemic and bleeding endpoints for patients who require short term anticoagulation in acute care settings," said John H. Alexander, MD, MHS, FACC of the Duke Clinica
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
2. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
3. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
4. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
5. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
6. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
7. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
8. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
9. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
10. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
11. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Needles Market 2014-2018" report to their offering. ... hypodermic needle is a hollow needle commonly used with ... or to extract fluids from it. A hypodermic needle ... inject substances that cannot be ingested. Hypodermic needles are ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the addition of the "Immunoprotein Diagnostic Testing ... at the highest CAGR of 6% and is ... report to their offering. ... for immunoprotein diagnostic testing has been segmented according ...
Breaking Medicine Technology:New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
(Date:7/13/2014)... (PRWEB) July 13, 2014 The ... Copper, Molybdenum, Iron), Form (Chelated & Non Chelated), ... Geography - Global Trends and Forecast to 2018” ... with an analysis and forecasting of the global ... identifies the driving and restraining factors for the ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study ... Scanning; 3D rendering; Layout and Animation; Image Reconstruction]: ... 2018)”, which analyzes and studies the major market ... Europe, Eastern Europe, Middle East and Africa, Asia-Pacific ... competitive landscape of the 3D imaging market, providing ...
(Date:7/13/2014)... 2014 Athletes with a certain genetic ... concussions, according to research presented today at the American ... Meeting. The research marks the first of its kind ... known physical events that occur after a head injury. ... allele in the (GT)n genotype were four times more ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular suppliers of ... its new range of elegant Quinceanera dresses . ... discounted prices. Worldwide clients can enjoy this special offer ... online shop, there are plenty of beautiful dresses for ... materials. MyDressCity.com’s hot items are prom gowns, bridesmaid gowns, ...
(Date:7/13/2014)... decreased ability to identify odors might indicate the ... examinations of the eye could indicate the build-up ... the brain, according to the results of four ... International Conference 2014 (AAIC 2014) in Copenhagen. , ... to identify odors was significantly associated with loss ...
Breaking Medicine News(10 mins):Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
... How your food is cooked may be as important to ... about a new class of toxins that might soon become// ... disorders as trans fats. ,This class of ... the body through the consumption of grilled, fried, or broiled ...
... model of infantile spasms, improving the likelihood of finding ... suffer from these catastrophic epilepsy seizures, according to research. ... epilepsy seizure seen in infancy and early childhood. The ... the body, arms, and legs. The seizures typically last ...
... experience great difficulties in prison, but people such as drug ... to a study in the latest Journal of Advanced Nursing. ... the Faculty of Health and Social Care at the University ... of 111 prisoners in 12 prisons across the UK. ...
... of Medicine has helped confirm the reliability of a ... genetic makeup. ,The Stanford group was one ... genetic test can identify patients who are at high ... That means high-risk patients could be directed toward a ...
... has been a surge of teen suicides. In this space, ... lives in despair. However, this one is// different, and explains ... ,A teenage girl, called Ebony (name changed to protect ... to attempts of ending her life several times. She responded ...
... of pneumonia at the Sipahijala wildlife sanctuary-cum-zoo in Tripura, officials ... suffered from a bout of pneumonia as the state was ... ,"Inadequate sheds and enclosures in the zoo had ... open sky while it was raining heavily. The deaths occurred ...
Cached Medicine News:Health News:Food Preparation may Play a Bigger Role in Chronic Disease 2Health News:Food Preparation may Play a Bigger Role in Chronic Disease 3Health News:Food Preparation may Play a Bigger Role in Chronic Disease 4Health News:Chronically Ill Prisoners Face Great Healthcare Problems 2Health News:Chronically Ill Prisoners Face Great Healthcare Problems 3Health News:New Test Helps Identify Hepatitis C Patients at High Risk of Developing Cirrhosis 2Health News:New Test Helps Identify Hepatitis C Patients at High Risk of Developing Cirrhosis 3Health News:Dispirited Teens Work Up Team Spirit to End Their Lives 2
Inquire...
Quick Release Holder for the 8000 Series Sliding Microtome. A simple to use hlder for wax cassettes. Accepts standard size wax cassettes (26 x 31 x 5mm). Can be specified instead of standard vice ...
Tilt Adapter for the 8000 Sliding Microtome to allow for orientation of the specimen....
... new SureCut M3500 Radial Microtome has a look ... and a range of functions and capabilities that ... Based on years of experience and knowledge but ... the SureCut M3500 Microtome will be the answer ...
Medicine Products: